Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Lexaria Bioscience's Business Segments
Lexaria Bioscience's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
3
Largest Segment
IP Licensing
Total Revenue
-
Regions Reported
-
Revenue Share by Reportable Segment - FY
- IP Licensing0%
- Intellectual Property Licensing0%
- B Two B0%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| IP Licensing | $ 0 | - |
| Intellectual Property Licensing | $ 0 | - |
| B Two B | - | - |
Annual Results
Revenue Share by Reportable Segment - FY
- IP Licensing0%
- Intellectual Property Licensing0%
- B Two B0%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| IP Licensing | $ 0 | - |
| Intellectual Property Licensing | $ 0 | - |
| B Two B | - | - |
Description of Lexaria Bioscience
Lexaria Bioscience Corp is a biotechnology company that focuses on developing and commercializing novel drug delivery platforms. The company is headquartered in Canada and operates in the healthcare sector. Lexaria Bioscience is listed on the Nasdaq Stock Market under the ticker symbol LEXX and on the Canadian Securities Exchange under the ticker symbol LXX.
The primary goal of Lexaria Bioscience is to enhance the effectiveness of existing drugs and active ingredients through their patented DehydraTECHTM drug delivery technology. This technology aims to improve the delivery of pharmaceuticals by increasing their bioavailability, or the amount of the drug that enters the bloodstream and is available to exert its therapeutic effects. By improving the bioavailability, Lexaria Bioscience aims to provide patients with more effective and consistent treatment options.
The DehydraTECHTM technology is based on a formulation technique that enhances the solubility and permeability of drugs and active ingredients. The technology works by encapsulating the drugs or active ingredients within lipid nanoparticles, which are then coated with a water-soluble shell. This unique approach improves the oral absorption of drugs, leading to faster onset of action, increased efficacy, and reduced dosing requirements.
Lexaria Bioscience has conducted extensive research and development to demonstrate the effectiveness of its drug delivery platform. The company has collaborated with numerous pharmaceutical and biotechnology companies to test the DehydraTECHTM technology with various drugs, including nonsteroidal anti-inflammatory drugs (NSAIDs), antivirals, cannabinoids, and nicotine.
One of the significant advantages of the DehydraTECHTM technology is its versatility. It can be applied to many different types of drugs, including those with poor water solubility, such as cannabinoids. This opens up new possibilities for oral drug delivery and allows for alternative administration methods, like tablets, capsules, or beverages.
In addition to the pharmaceutical sector, Lexaria Bioscience has also entered the cannabis industry. The company has developed DehydraTECHTM-enabled CBD products, including both ingestible and topical formulations. The cannabis market presents significant opportunities for Lexaria Bioscience, as it continues to expand globally.
Lexaria Bioscience's business model revolves around licensing its patented DehydraTECHTM technology to other companies in exchange for royalties and commercialization rights. This allows the company to leverage its innovation and intellectual property without having to manufacture and market its own drugs. By partnering with established pharmaceutical or cannabis companies, Lexaria Bioscience can tap into their existing distribution networks and accelerate the commercialization process.
Overall, Lexaria Bioscience Corp is a biotechnology company focused on revolutionizing drug delivery through its patented DehydraTECHTM technology. With its potential to enhance the bioavailability of pharmaceuticals and improve patient outcomes, the company is well-positioned to disrupt the drug delivery market and create significant value for its shareholders.
The primary goal of Lexaria Bioscience is to enhance the effectiveness of existing drugs and active ingredients through their patented DehydraTECHTM drug delivery technology. This technology aims to improve the delivery of pharmaceuticals by increasing their bioavailability, or the amount of the drug that enters the bloodstream and is available to exert its therapeutic effects. By improving the bioavailability, Lexaria Bioscience aims to provide patients with more effective and consistent treatment options.
The DehydraTECHTM technology is based on a formulation technique that enhances the solubility and permeability of drugs and active ingredients. The technology works by encapsulating the drugs or active ingredients within lipid nanoparticles, which are then coated with a water-soluble shell. This unique approach improves the oral absorption of drugs, leading to faster onset of action, increased efficacy, and reduced dosing requirements.
Lexaria Bioscience has conducted extensive research and development to demonstrate the effectiveness of its drug delivery platform. The company has collaborated with numerous pharmaceutical and biotechnology companies to test the DehydraTECHTM technology with various drugs, including nonsteroidal anti-inflammatory drugs (NSAIDs), antivirals, cannabinoids, and nicotine.
One of the significant advantages of the DehydraTECHTM technology is its versatility. It can be applied to many different types of drugs, including those with poor water solubility, such as cannabinoids. This opens up new possibilities for oral drug delivery and allows for alternative administration methods, like tablets, capsules, or beverages.
In addition to the pharmaceutical sector, Lexaria Bioscience has also entered the cannabis industry. The company has developed DehydraTECHTM-enabled CBD products, including both ingestible and topical formulations. The cannabis market presents significant opportunities for Lexaria Bioscience, as it continues to expand globally.
Lexaria Bioscience's business model revolves around licensing its patented DehydraTECHTM technology to other companies in exchange for royalties and commercialization rights. This allows the company to leverage its innovation and intellectual property without having to manufacture and market its own drugs. By partnering with established pharmaceutical or cannabis companies, Lexaria Bioscience can tap into their existing distribution networks and accelerate the commercialization process.
Overall, Lexaria Bioscience Corp is a biotechnology company focused on revolutionizing drug delivery through its patented DehydraTECHTM technology. With its potential to enhance the bioavailability of pharmaceuticals and improve patient outcomes, the company is well-positioned to disrupt the drug delivery market and create significant value for its shareholders.
Lexaria Bioscience Corp focuses primarily on the biotechnology sector, particularly in the area of drug delivery and bioavailability enhancement. The company is known for its proprietary technologies designed to improve the absorption of medical compounds, primarily cannabinoids, through alternative delivery methods. Here is an extensive overview of the segments, products, and services they offer:
Segments
1. Cannabinoid Delivery Systems:
Lexaria has developed a patented technology known as DehydraTECH™. This technology is designed to enhance the bioavailability of cannabinoids, allowing for more effective delivery of these compounds in various consumer products. This segment primarily targets the medical and recreational cannabis markets, focusing on improving the delivery mechanisms for cannabinoids like CBD and THC.
2. Pharmaceuticals:
Lexaria is exploring the use of its DehydraTECH™ technology in the pharmaceutical industry. This includes the development of formulations for various therapeutic compounds, not limited to cannabinoids but also extending to non-cannabinoid pharmaceutical drugs that can benefit from enhanced absorption.
3. Nutraceuticals:
The company also operates in the nutraceutical space, working on products that include vitamins, supplements, and other dietary products. The goal is to leverage their technology to create formulations that provide better efficacy and faster onset of effects, contributing to overall wellness.
Products
1. DehydraTECH™ Technology:
The cornerstone of Lexarias offerings, DehydraTECH™ allows for the rapid and efficient absorption of active ingredients in the body. The technology has applications across multiple product categories and aims to minimize the time it takes for users to feel effects.
2. Infused Edibles:
Lexaria offers a range of infused edible products, primarily in the form of snacks, beverages, and other consumables. These products utilize the DehydraTECH™ technology to ensure that cannabinoids are absorbed more quickly compared to traditional edibles, which often lead to delayed effects.
3. Functional Beverages:
The company has ventured into the beverage market, creating drinks infused with cannabinoids that utilizes their advanced delivery system. This segment aims to provide consumers with an enjoyable way to consume cannabinoids that is also effective.
4. Topicals:
Lexaria is also working on topical products infused with cannabinoids. These products are designed for direct application to the skin, addressing localized discomfort while ensuring optimal bioavailability.
5. Pharmaceutical Formulations:
The company is in the process of developing specific pharmaceutical formulations that use the DehydraTECH™ technology to enhance the efficacy and absorption of various drugs, possibly targeting specific medical conditions.
Services
1. Research and Development:
Lexaria invests significantly in R&D to explore new applications for its technology across various sectors. This includes conducting studies to back the efficacy of its products and expanding its intellectual property portfolio.
2. Contract Manufacturing:
Lexaria offers services related to the production of its proprietary formulations. By partnering with established manufacturers, the company can scale production of its products while ensuring quality and consistency.
3. Partnerships and Collaborations:
The company often engages in strategic partnerships with other firms to develop new products or enter new markets. This collaborative approach aims to leverage the strengths of various stakeholders in the biotechnology and cannabis sectors.
4. Consulting Services:
Lexaria provides consulting services related to cannabinoid formulations, bioavailability, and product development. This service is aimed at other businesses looking to enhance their product offerings and improve efficacy through advanced delivery systems.
In summary, Lexaria Bioscience Corp is at the forefront of innovative drug delivery systems, with a strong focus on enhancing the bioavailability of cannabinoids through their proprietary technology. They operate in various market segments, offering a diverse range of products and services tailored to consumer needs and the demands of the pharmaceutical landscape.
Segments
1. Cannabinoid Delivery Systems:
Lexaria has developed a patented technology known as DehydraTECH™. This technology is designed to enhance the bioavailability of cannabinoids, allowing for more effective delivery of these compounds in various consumer products. This segment primarily targets the medical and recreational cannabis markets, focusing on improving the delivery mechanisms for cannabinoids like CBD and THC.
2. Pharmaceuticals:
Lexaria is exploring the use of its DehydraTECH™ technology in the pharmaceutical industry. This includes the development of formulations for various therapeutic compounds, not limited to cannabinoids but also extending to non-cannabinoid pharmaceutical drugs that can benefit from enhanced absorption.
3. Nutraceuticals:
The company also operates in the nutraceutical space, working on products that include vitamins, supplements, and other dietary products. The goal is to leverage their technology to create formulations that provide better efficacy and faster onset of effects, contributing to overall wellness.
Products
1. DehydraTECH™ Technology:
The cornerstone of Lexarias offerings, DehydraTECH™ allows for the rapid and efficient absorption of active ingredients in the body. The technology has applications across multiple product categories and aims to minimize the time it takes for users to feel effects.
2. Infused Edibles:
Lexaria offers a range of infused edible products, primarily in the form of snacks, beverages, and other consumables. These products utilize the DehydraTECH™ technology to ensure that cannabinoids are absorbed more quickly compared to traditional edibles, which often lead to delayed effects.
3. Functional Beverages:
The company has ventured into the beverage market, creating drinks infused with cannabinoids that utilizes their advanced delivery system. This segment aims to provide consumers with an enjoyable way to consume cannabinoids that is also effective.
4. Topicals:
Lexaria is also working on topical products infused with cannabinoids. These products are designed for direct application to the skin, addressing localized discomfort while ensuring optimal bioavailability.
5. Pharmaceutical Formulations:
The company is in the process of developing specific pharmaceutical formulations that use the DehydraTECH™ technology to enhance the efficacy and absorption of various drugs, possibly targeting specific medical conditions.
Services
1. Research and Development:
Lexaria invests significantly in R&D to explore new applications for its technology across various sectors. This includes conducting studies to back the efficacy of its products and expanding its intellectual property portfolio.
2. Contract Manufacturing:
Lexaria offers services related to the production of its proprietary formulations. By partnering with established manufacturers, the company can scale production of its products while ensuring quality and consistency.
3. Partnerships and Collaborations:
The company often engages in strategic partnerships with other firms to develop new products or enter new markets. This collaborative approach aims to leverage the strengths of various stakeholders in the biotechnology and cannabis sectors.
4. Consulting Services:
Lexaria provides consulting services related to cannabinoid formulations, bioavailability, and product development. This service is aimed at other businesses looking to enhance their product offerings and improve efficacy through advanced delivery systems.
In summary, Lexaria Bioscience Corp is at the forefront of innovative drug delivery systems, with a strong focus on enhancing the bioavailability of cannabinoids through their proprietary technology. They operate in various market segments, offering a diverse range of products and services tailored to consumer needs and the demands of the pharmaceutical landscape.